Posted by Michael Wonder on 17 Jun 2022
Skyrizi (risankizumab-rzaa) receives FDA approval as the first and only specific interleukin-23 to treat moderately to severely active Crohn's disease in adults
17 June 2022 - Third approved indication for risankizumab-rzaa is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY.
AbbVie today announced that the U.S. FDA has approved Skyrizi (risankizumab-rzaa) as the first and only specific interleukin-23 inhibitor for the treatment of adults with moderately to severely active Crohn's disease.
